In mouse models of insulin–resistance treatment, FGF21 increased energy expenditure, reduced plasma circulating levels of glucose, improved liver steatosis, and improved both leptin and insulin sensitivity (71, 72). This evidence concerns the gene INS and Hepatic steatosis.